A share price of Ultragenyx Pharmaceutical Inc [RARE] is currently trading at $36.40, up 0.72%. An important factor to consider is whether the stock is rising or falling in short-term value. The RARE shares have gain 3.76% over the last week, with a monthly amount drifted -7.38%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Goldman upgraded its rating to Buy on June 06, 2024, and elevated its price target to $67. On April 22, 2024, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $77 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $72 on December 08, 2023. Evercore ISI upgraded its rating to Outperform for this stock on June 06, 2023, and upped its price target to $80. In a note dated April 26, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $114 on this stock.
Ultragenyx Pharmaceutical Inc experienced fluctuations in its stock price throughout the past year between $29.59 and $60.37. Currently, Wall Street analysts expect the stock to reach $89.5 within the next 12 months. Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] shares were valued at $36.40 at the most recent close of the market. An investor can expect a potential return of 145.88% based on the average RARE price forecast.
Analyzing the RARE fundamentals
Trailing Twelve Months sales for Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] were 590.69M which represents 27.99% growth. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.87%, Pretax Profit Margin comes in at -0.93%, and Net Profit Margin reading is -0.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -1.86 and Total Capital is -0.5. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.84 points at the first support level, and at 35.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.90, and for the 2nd resistance point, it is at 37.41.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] is 2.40. On the other hand, the Quick Ratio is 2.24, and the Cash Ratio is 0.44. Considering the valuation of this stock, the price to sales ratio is 5.83, the price to book ratio is 23.66.
Transactions by insiders
Recent insider trading involved Crombez Eric, EVP and Chief Medical Officer, that happened on May 05 ’25 when 520.0 shares were sold. EVP and Chief Medical Officer, Crombez Eric completed a deal on Apr 21 ’25 to sell 242.0 shares. Meanwhile, Chief Financial Officer Horn Howard sold 1785.0 shares on Mar 06 ’25.
